Published in Nephrourol Mon on June 08, 2013
Molecular Imaging of Prostate Cancer. Radiographics (2015) 1.51
SULF2 overexpression positively regulates tumorigenicity of human prostate cancer cells. J Exp Clin Cancer Res (2015) 0.84
NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer. Cancer Biol Ther (2015) 0.78
Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and treatment-related changes. Biomed Res Int (2015) 0.78
Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions. J Cancer (2016) 0.77
Comparative Analysis of Prostate Cancer Gene Regulatory Networks via Hub Type Variation. Avicenna J Med Biotechnol (2015) 0.77
Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer. PLoS One (2015) 0.76
Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer. Oncotarget (2016) 0.75
Intrarectal Lidocaine-Diltiazem-Meperidine Gel for Transrectal Ultrasound Guided Prostate Biopsy. Anesth Pain Med (2015) 0.75
Oncolytic adenovirus-mediated therapy for prostate cancer. Oncolytic Virother (2016) 0.75
Human Prostate Cancer Hallmarks Map. Sci Rep (2016) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (1988) 14.66
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
Cancer epigenetics comes of age. Nat Genet (1999) 12.63
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A (1999) 4.90
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res (1992) 4.00
Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci U S A (1998) 3.89
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet (2002) 3.87
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet (2002) 3.67
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A (1992) 3.28
Family history and the risk of prostate cancer. Prostate (1990) 3.27
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science (2001) 3.22
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet (1998) 2.90
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst (2000) 2.87
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med (1995) 2.83
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics (1997) 2.65
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet (1998) 2.59
Carcinoma of the prostate. N Engl J Med (1991) 2.47
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
The impact of family history on early detection of prostate cancer. Nat Med (1995) 2.14
Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res (2000) 2.13
Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet (1999) 2.12
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res (1995) 1.98
Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97
Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene (1998) 1.97
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet (2002) 1.86
Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res (1998) 1.83
Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene (1999) 1.75
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70
Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet (2000) 1.69
Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet (2000) 1.65
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A (2001) 1.65
Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet (1998) 1.63
A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res (2004) 1.60
Dysregulation of the annexin family protein family is associated with prostate cancer progression. Am J Pathol (2003) 1.60
p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res (1993) 1.59
Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol (1998) 1.57
A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet (2000) 1.51
Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol (2003) 1.50
Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res (2004) 1.47
Annexin II expression is reduced or lost in prostate cancer cells and its re-expression inhibits prostate cancer cell migration. Oncogene (2003) 1.46
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol (1999) 1.46
The many roles of c-Myc in apoptosis. Annu Rev Physiol (1998) 1.44
Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res (1997) 1.44
DNA sequence amplification in human prostate cancer identified by chromosome microdissection: potential prognostic implications. Clin Cancer Res (1995) 1.44
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer (1997) 1.42
Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet (2002) 1.41
Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet (2001) 1.32
Familial prostate cancer in Sweden. A nationwide register cohort study. Cancer (1996) 1.30
Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol (1997) 1.29
Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst (1998) 1.28
NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res (2002) 1.25
NBS1 is a prostate cancer susceptibility gene. Cancer Res (2004) 1.24
Molecular pathology of prostate cancer. J Clin Pathol (2005) 1.22
ATBF1, a multiple-homeodomain zinc finger protein, selectively down-regulates AT-rich elements of the human alpha-fetoprotein gene. Mol Cell Biol (1994) 1.22
BCL-2 in prostate cancer: a minireview. Apoptosis (2003) 1.22
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst (1997) 1.19
Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer (2003) 1.19
An inducible null mutant murine model of Nijmegen breakage syndrome proves the essential function of NBS1 in chromosomal stability and cell viability. Hum Mol Genet (2004) 1.16
How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk? Cancer Epidemiol Biomarkers Prev (2004) 1.15
Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls. Cancer Res (2001) 1.13
Molecular biology of prostate-cancer pathogenesis. Curr Opin Urol (2006) 1.13
Hereditary prostate cancer: clinical aspects. J Urol (2002) 1.12
Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res (1996) 1.11
CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review. Am J Epidemiol (2004) 1.09
Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol (2003) 1.09
Molecular mechanisms of prostate cancer. Eur Urol (2004) 1.08
Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer. Am J Pathol (2004) 1.08
Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol (1998) 1.04
ERG gene rearrangement status in prostate cancer detected by immunohistochemistry. Virchows Arch (2011) 1.04
Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer (1994) 1.02
Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res (2003) 1.02
Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res (2002) 1.00
Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer (2003) 0.99
Molecular pathways to prostate cancer. J Urol (2003) 0.98
p53 oncogene mutations in human prostate cancer specimens. J Urol (1994) 0.98
Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer (1996) 0.97
Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene (1998) 0.96
Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer. Clin Prostate Cancer (2003) 0.96
Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 0.96
Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells. Br J Cancer (1999) 0.96
Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci (2001) 0.95